In conclusion, TMB and the inflammatory biomarkers PD‐L1 CPS and TcellinfGEP were each significantly and independently predictive of response to pembrolizumab in patients with HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.